Crossref
Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria
European Journal of Dermatology · 2023
DOI: 10.1684/ejd.2023.4563 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Dermatology, 2023. Verfasst von Cliodhna Murray und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Chronic Urticaria, Anti-Allergic Agents, Urticaria.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Chronic UrticariaAnti-Allergic AgentsUrticariaHumansOmalizumabCosts and Cost AnalysisChronic DiseaseTreatment Outcome
Substanzen
OmalizumabAnti-Allergic Agents
Zitieren
APA
Murray, C., Ridge, K., & Conlon, N. (2023). Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria. European Journal of Dermatology. https://doi.org/10.1684/ejd.2023.4563
Vancouver
Murray C, Ridge K, Conlon N. Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria. European Journal of Dermatology. 2023. doi:10.1684/ejd.2023.4563
BibTeX
@article{Murray2023,
author = {Murray, Cliodhna and Ridge, Katie and Conlon, Niall},
title = {Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria},
journal = {European Journal of Dermatology},
year = {2023},
doi = {10.1684/ejd.2023.4563}
}
EUVIMED